Cite
HARVARD Citation
Bahig, H. et al. (2022). Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC). Clinical and translational radiation oncology. pp. 115-119. [Online].